In: Non-small cell lung cancer

Patritumab deruxtecan

Daiichi Sankyo · Merck & Co. · U3-1402 · HER3-DXd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
16 active
18 in total · 13 in the EU
Targets
 

What this is

How it works
HER3-targeted antibody-drug conjugate
How it’s given
“Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.”In the company’s words, NCT04619004 on ClinicalTrials.gov
Tested for
Breast Neoplasms (3 trials), Breast Cancer (3 trials), Non-small Cell Lung Cancer (NSCLC) (3 trials), Gastroesophageal Junction (2 trials), Gastroesophageal Adenocarcinoma (2 trials), Esophageal Neoplasms (2 trials), Esophageal Cancer (2 trials), Nonsquamous Non-small Cell Lung Cancer and 24 more
Main trialPhase 3
“Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile. There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggests that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.”In the company’s words, NCT05338970 on ClinicalTrials.gov
Other names
U3-1402 · HER3-DXd

Other drugs for Breast Neoplasms

All 396 drugs for Breast Neoplasms

Coming up12

Changes1

Last 90 days

Trials18

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 31 May 2024 HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Phase 3Recruiting 14 Jul 2033 A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 2Active, not recruiting 21 Nov 2022 HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Phase 2Recruiting 31 Dec 2029 Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Phase 2Recruiting 19 Nov 2030 A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2Recruiting 12 Mar 2032 A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Phase 1/2Recruiting 9 May 2028 Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Phase 1/2Active, not recruiting 7 Dec 2028 Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Phase 1/2Recruiting 17 Aug 2029 A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Phase 1/2Recruiting 12 Sep 2029 Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Phase 1/2Recruiting 30 Dec 2030 A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Phase 1/2Recruiting 1 Jan 2031 A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Phase 1/2Recruiting 13 Feb 2032 KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Phase 1/2Recruiting 2 Aug 2032 Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Phase 1Active, not recruiting 31 Jan 2025 HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
Phase 1Active, not recruiting 1 Dec 2025 U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Phase 2Terminated 3 Feb 2022 A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
Phase 1/2Completed 16 Aug 2021 Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Patritumab deruxtecan

Following is part of Solo: you see every change to Patritumab deruxtecan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in